Theratechnologies Inc. (NASDAQ:THTX) Sees Significant Growth in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 13,800 shares, an increase of 81.6% from the August 15th total of 7,600 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 37,100 shares, the short-interest ratio is currently 0.4 days.

Theratechnologies Trading Up 8.9 %

Shares of THTX traded up $0.11 during midday trading on Friday, hitting $1.35. The stock had a trading volume of 26,212 shares, compared to its average volume of 45,056. Theratechnologies has a fifty-two week low of $0.88 and a fifty-two week high of $2.58. The business has a 50-day simple moving average of $1.37 and a two-hundred day simple moving average of $1.35. The firm has a market cap of $62.07 million, a P/E ratio of -7.11 and a beta of 1.41.

Theratechnologies (NASDAQ:THTX) last announced its earnings results on Wednesday, July 10th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.04. The firm had revenue of $22.02 million during the quarter. During the same period last year, the firm posted ($0.40) EPS. On average, analysts expect that Theratechnologies will post -0.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AIGH Capital Management LLC boosted its holdings in shares of Theratechnologies by 362.9% in the fourth quarter. AIGH Capital Management LLC now owns 3,719,302 shares of the company’s stock worth $6,025,000 after buying an additional 2,915,906 shares during the period. Worth Venture Partners LLC boosted its holdings in shares of Theratechnologies by 362.5% during the fourth quarter. Worth Venture Partners LLC now owns 906,557 shares of the company’s stock worth $1,469,000 after purchasing an additional 710,551 shares during the period. Finally, National Bank of Canada FI boosted its holdings in shares of Theratechnologies by 65.4% during the fourth quarter. National Bank of Canada FI now owns 113,378 shares of the company’s stock worth $191,000 after purchasing an additional 44,825 shares during the period.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.